Novel Proenzyme Pharmaceutical Formulation to be Administered by Intravenous (I.V.) Injection in World First, Phase I First-In-Human Study in Advanced Cancer Patients
MELBOURNE, Australia, May 18, 2022--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company is undertaking manufacturing and development of PRP for human use. PRP is the Company’s lead product candidate and is a novel pharmaceutical formulation consisting of two proenzymes to be administered by I.V. injection in a world first, First-In-Human (FIH) study in advanced cancer patients. It is a long-term therapy for the treatment and prevention of metastatic cancer in patients suffering from solid tumors.
To date, the Company has sourced the two proenzymes from a raw material supplier, where an isolation process for both ingredients have been established and scaled up. The proenzymes are extracted, precipitated and lyophilized (freeze dried by a low temperature dehydration process), serving as the raw materials for GMP (Good Manufacturing Practice) manufacture of the finished drug product. A proprietary purification process has been developed by Propanc and successful scale up of the bulk drug substances has been completed. Over 95% purity for each of the proenzymes was achieved to reach pharmaceutical standard for the final drug product. This reduces impurities, resulting in a more stable product with a longer shelf life, as the active enzymes have the potential to ‘auto-catalyze’ meaning they can potentially self-activate. Therefore, the novel formulation consists of two proenzymes prepared in individual vials ready to be mixed into a solution for I.V. injection for the upcoming Phase I, FIH study.
According to Dr. Linda Isaacs M.D., Integrative Cancer Therapies, January 2022, since the turn of the last century, based on the original hypothesis of Professor John Beard from Edinburgh University, the trophoblastic theory and the origin of cancer, numerous physicians have been injecting enzyme preparations into cancer patients with both startling, but also mixed success. One reason was attributed by Beard to the "wide variation" in the quality available enzymes that he believed explained why the treatment was sometimes unsuccessful. In the following years, there were numerous attempts at injection of enzymes, which led to the US Food and Drug Administration prohibiting intravenous and injectable enzymes, presumably due to the uncontrolled nature of the administration to patients. Despite this, Dr Isaacs concludes that an intravenous formulation for use in humans would offer "considerable advantages", whilst also acknowledging the considerable developmental costs.
Over the last decade, Propanc has undertaken the manufacturing and development of proenzymes as an I.V. formulation and conducted several scientific advice meetings with the Medicines and Healthcare Products Regulatory Agency (MHRA) UK to determine the pathway for the clinical development of PRP. The Company has also sourced suitable quality proenzymes for the commercial scale quantities needed for global pharmaceutical distribution and is ready to undertake the full scale GMP manufacture of PRP in preparation for the upcoming Phase I FIH study in advanced cancer patients.
"We have spent significant time and resources on the manufacturing and development of PRP as we prepare for our Phase I, FIH study in advanced cancer patients," said James Nathanielsz, Propanc’s Chief Executive Officer. "Undertaking the steps necessary to purify and scale up the bulk drug substances is critical to producing a quality product according to pharmaceutical standard, which we intend to seek regulatory approval for worldwide distribution. Our novel pharmaceutical formulation is a world-first approach using a technology with over 100 years of clinical experience, since Professor John Beard first proposed the use of enzymes as a novel way to treat cancer. By advancing PRP through the drug development process, we remain committed to achieving a vision of producing a long-term approach for the treatment and prevention of metastatic cancer from solid tumors, which remains the main cause of patient death for sufferers."
Professor Klaus Kutz, Propanc’s Chief Medical Officer said, "Our lead product candidate, PRP, is a novel, targeted cancer therapy, free from the side effects normally associated with standard treatment approaches. That is why we have worked over several years to overcome the technical challenges to produce a novel pharmaceutical formulation to GMP standard for I.V injection, which is our preferred route of administration in order to increase systemic exposure to treat solid tumors, which may result in better therapeutic efficacy."
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine and skin cancers.
Propanc Biopharma, Inc. (the "Company") is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
To view the Company’s "Mechanism of Action" video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
All statements other than statements of historical facts contained in this press release are "forward-looking statements," which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successful develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005503/en/
Investor Relations and Media: Mr. James Nathanielsz Propanc Biopharma, Inc. irteam@propanc.com +61-3-9882-0780
Athersys Inc's (NASDAQ: ATHX) partner, Healios K.K. has reported topline results for its Japan ischemic stroke study, TREASURE. The study included patients with moderate to moderate-severe ischemic stroke administered a single dose of MultiStem cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The primary endpoint, Excellent Outcome at 90 days, did not reach statistical significance in this population. Overall, consistent improvement in essentially all mea
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
The opinion marks the first step toward European regulatory approval of the oral JAK inhibitor for the treatment of adults with severe alopecia areata.
Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. The second reason has to do with Moderna specifically. The company's only commercialized product right now is the coronavirus vaccine, so investors worry about earnings if vaccine demand drops in a post-pandemic world.
The biotech company announced on Thursday that the Food and Drug Administration placed a hold on its leukemia study.
Science produced some wonderful news this week for members of the Mesocricetus auratus community -- more commonly known as hamsters. Data on a preclinical trial of Vaxart's (VXRT) oral and intranasal anti-coronavirus vaccine candidate, published in the peer-reviewed journal Science Translational Medicine, showed that hamsters treated with the COVID-19 vaccine candidate targeting "S" proteins in the SARS-CoV-2 coronavirus were less able to transmit the virus. Additionally, a Phase I clinical tria
(Bloomberg) -- Shares of companies that develop or make therapies to combat viral outbreaks, such as SIGA Technologies Inc. and Emergent BioSolutions Inc., rallied Thursday as the first case of monkeypox arrives in the US this year and new cases appear in the UK.Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightChina in Talks With Russia to Buy Oil for Strategic ReservesApple Shows AR/VR Headset to Board in Sign of Progress on Key Proje
The FDA approved the intravenous (IV) formulation of SIGA Technologies Inc's (NASDAQ: SIGA) TPOXX for smallpox. The oral formulation of TPOXX (tecovirimat) is approved in the US, Canada, and Europe to treat smallpox. The European approval also includes the treatment of monkeypox, cowpox, and complications from immunization with vaccinia. The IV formulation of TPOXX was cited in the recent U.S. president's budget request as being used to treat a patient in the U.S. with monkeypox. Related: What I
Novavax stock was dropping Friday after receiving a Sell-equivalent rating — the first since December 2020 and the only one from Wall Street. Bank of America Securities analyst Alec Stranahan initiated coverage of Novavax (ticker: NVAX ) at an Underperform rating on Friday, with a $35 price target. Despite the pullback, Stranahan sees room for the shares to trade lower still.
More than two years into the COVID pandemic, it's clear that people are very much over the virus. Most of us are gathering with loved ones and planning vacations, while health officials have stripped back mask mandates and dropped vaccine requirements. But the coronavirus still continues to wreak havoc across the U.S. In just the last week alone, cases in the country have increased by more than 30 percent and hospitalizations by over 17 percent, according to the Centers for Disease Control and P
In the winter 2019, Kavita Juneja found herself at the center of a maelstrom. A strange and deadly virus known as SARS-CoV-2 was hurtling across the globe.
Marcia Herman-Giddens first realized something was changing in young girls in the late 1980s, while she was serving as director for the child abuse team at Duke University Medical Center in Durham, North Carolina. During evaluations of girls who had been abused, Herman-Giddens noticed that many of them had started developing breasts as young as 6 or 7. “That did not seem right,” said Herman-Giddens, who is now an adjunct professor at the University of North Carolina Gillings School of Global Pub
The daily average for new COVID-19 cases topped the 100,000 mark of the third straight day and hospitalizations keep rising, but deaths fell to a 10-month low. Meanwhile, advisors to the Centers for Disease Control and Prevention recommended that children aged 5 to 11 receive the COVID-19 booster shot from Pfizer Inc. and BioNTech SE that was cleared by the Food and Drug Administration earlier this week. The seven-day average of new cases was 103,537 on Thursday, up 52% from two weeks ago and th
Amid rising concerns over the potential development of resistance to Pfizer Inc's (NYSE: PFE) COVID-19 pill Paxlovid, the company has declined to supply researchers with the antiviral for use in combination studies, according to a Bloomberg report. Researchers say that Paxlovid combined with other drugs might stave off resistance. Pfizer hasn't started any combination trials in people, and a review of the clinicaltrials.gov database shows no outpatient combination studies with Paxlovid. Efforts
The World Health Organization was holding an emergency meeting on Friday to discuss the recent outbreak of monkeypox, a viral infection more common to west and central Africa, after over 100 cases were confirmed or suspected in Europe. In what Germany described as the largest outbreak in Europe ever, cases have been reported in at least nine countries – Belgium, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden and the United Kingdom - as well as the United States, Canada and Australia. Spain reported 24 new cases on Friday, mainly in the Madrid region where the regional government closed a sauna linked to the majority of infections.
Shares of Emergent BioSolutions were rising sharply Thursday. The drugmaker produces a vaccine that can help prevent people from getting monkeypox. The U.S. confirmed a case of monkeypox on Wednesday in a man in Massachusetts who recently traveled to Canada.
The actress talks misogony and mental health.
Top infant formula makers, including Reckitt Benckiser, Nestle and Danone SA, are also ramping up supplies to the country. Abbott recalls dozens of types of powdered baby formulas, including Similac, Alimentum and EleCare, made at its Sturgis, Michigan plant after four consumers complained about bacterial infections in infants who had consumed those products; Recalled products had an expiry date of April 1, 2022 or later. China's custom officials warn consumers against buying and consuming certain of Abbott's infant and baby products.
The 29-year-old actress and model shared a photo of her latest fitness feat on Instagram.
In a sign of the public's waning pandemic fears, Clorox CEO Linda Rendle announced the company would scale back production as covid-19 shifts to “more of an endemic phase."